Focusing effects of L-dopa in Parkinson's disease.
نویسندگان
چکیده
Previous fMRI motor studies in Parkinson's disease (PD) have suggested that L-dopa may "normalize" areas of hypo- and hyperactivity. However, results from these studies, which were largely based on analyzing BOLD signal amplitude, have been conflicting. Examining only amplitude changes at distinct loci may thus be inadequate in fully capturing the activation changes induced by L-dopa. In this article, we extended prior analyses on the effects of L-dopa by investigating both amplitude and spatial changes of brain activation before and after L-dopa. Ten subjects with PD, both on and off medication, and ten healthy, age-matched controls performed a visuo-motor tracking task in which they sinusoidally squeezed a bulb at 0.25, 0.5, and 0.75 Hz. This task was contrasted with static squeezing to generate fMRI activation maps. To investigate the effects of L-dopa, we examined the amplitude and spatial variance of the BOLD response within anatomically-defined regions of interest (ROIs). L-dopa had significant main effects on the amplitude of BOLD signal in bilateral primary motor cortex and left SMA. In contrast, L-dopa-mediated spatial changes were apparent in bilateral cerebellar hemispheres, M1, SMA, and right prefrontal cortex. Moreover, L-dopa appeared to normalize the spatial distribution of ROI activation in PD to that of the controls. Specifically, L-dopa had a "focusing" effect on activity-an effect more pronounced than the typically-measured fMRI amplitude changes. This observation is consistent with modeling studies, which demonstrated that dopamine increases the signal-to-noise ratio at the neuronal level with a resultant focusing of representations at the macroscopic level.
منابع مشابه
Effect of levodopa on cognitive function in Parkinson's disease with and without dementia and dementia with Lewy bodies.
BACKGROUND Levodopa (L-dopa) is the gold standard treatment for Parkinson's disease, but a lack of clear efficacy combined with a perceived liability to neuropsychiatric side effects has limited L-dopa use in patients with parkinsonism and dementia. Therefore, the effect of L-dopa on the cognitive profile of dementia with Lewy bodies (DLB) and Parkinson's disease with dementia (PDD) is unclear....
متن کاملLong-term treatment of Parkinson's disease with bromocriptine.
BRomocriptine (15-75 mg per day) alone or with L-dopa was studied during five to 29 months on 44 patients with Parkinson's disease. Used as sole therapeutic agent, it was found excellent in 12 patients who had never received regular L-dopa treatment either because it was never attempted or because of intolerance from the outset. Its anti-Parkinsonism activity was comparable with L-dopa. The gai...
متن کاملBromocriptine and the clinical spectrum of Parkinson's disease.
As the direct agonist with the widest clinical use, bromocriptine provides a unique window into the clinical spectrum of Parkinson's disease. The efficacy of bromocriptine for therapy of de novo Parkinson's disease has recently been confirmed using a double-blind design with L-Dopa (Sinemet). Over a period of 5.5 months, bromocriptine was found to be as effective as L-Dopa in reducing the funct...
متن کاملImbalanced Dopaminergic Transmission Mediated by Serotonergic Neurons in L-DOPA-Induced Dyskinesia
L-DOPA-induced dyskinesias (LIDs) are one of the main motor side effects of L-DOPA therapy in Parkinson's disease. The review will consider the biochemical evidence indicating that the serotonergic neurons are involved in the dopaminergic effects of L-DOPA in the brain. The consequences are an ectopic and aberrant release of dopamine that follows the serotonergic innervation of the brain. After...
متن کاملDopaminergic modulation of high-level cognition in Parkinson's disease: the role of the prefrontal cortex revealed by PET.
This study examined the effects of L-dopa medication in patients with Parkinson's disease on cortical and subcortical blood flow changes during two tasks known to involve frontostriatal circuitry. Eleven patients with Parkinson's disease were scanned on two occasions, one ON L-dopa medication and one OFF L-dopa medication, during performance of the Tower of London planning task and a related te...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Human brain mapping
دوره 31 1 شماره
صفحات -
تاریخ انتشار 2010